drugset
drugset / Trial / NCT01688089

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-103 in Healthy Volunteers

NCT01688089 ↗

Phase 1 Completed 67 enrolled Orion Corporation, Orion Pharma
RandomizedCrossoverDouble-blind

Summary

The purpose of this study is to evaluate the safety and tolerability of escalating doses of ODM-103 when given to healthy male volunteers.

Timeline

Start
2012-09
Primary completion
2014-09
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Entacapone Small molecule 200 mg Oral
Comparator Levodopa/carbidopa Unknown — Oral
Subject ODM-103 Unknown — Oral

Indications

No indication recorded.